RAND's divisions conduct research on a uniquely broad front for clients around the globe.
Most relevant regions
Research
Jan 19, 2015
We assessed physician experiences with drug shortages in a population-based cohort of medical oncologists caring for patients with lung or colorectal cancer.
Jan 9, 2015
Multiple recurrences develop in patients with high-risk non–muscle-invasive bladder cancer.
Commentary
Nov 18, 2014
CT lung cancer screening turns out to be like many new medical technologies: It improves health but is quite expensive. Moreover, it needs implementation that targets those most likely to benefit and provides them the care they need efficiently.
Nov 1, 2014
CT screening reduced death from lung cancer by 20% during a 6 year trial among heavy smokers age 50-74; the cost was about $81,000/QALY gained. If screening is extended to not-so-heavy smokers, its value falls dramatically, and radiation risks may outweigh screening gains.
Sep 26, 2014
Clinical trials are essential to establish the effectiveness of new cancer therapies, but less than 5% of adults with cancer enroll in trials.
Jul 1, 2014
The cancer stigma index can be used to inform initial cancer education efforts, identifying overall stigma levels in a country or community and particular issue areas requiring intervention.
Project
Jun 16, 2014
The UK Government currently invests approximately £1.6 billion in medical research each year, with the British public donating an additional £1.7 billion to medical research charities in 2012/13. Work by RAND Europe in collaboration with Brunel University and King’s College London provides evidence to support this continued investment in science by demonstrating how funding for cancer research delivers health gains for patients and benefits the UK economy.
Jun 15, 2014
RAND Europe and HERG were asked by UK medical research funders to investigate returns to public/charitable investment in cancer research. This report details the five case studies conducted as part of this work and observations emerging across them.
Mar 1, 2014
In many studies with a survival outcome, it is often not feasible to fully observe the primary event of interest. This often leads to heavy censoring and thus, difficulty in efficiently estimating survival or comparing survival rates between two groups.
Feb 1, 2014
Partial nephrectomy and radical nephrectomy may lead to adverse health outcomes.
Jan 1, 2014
An integrated, patient-centered model for individuals with advanced urologic malignancies is feasible and well received by practitioners.
We estimated the effect of anecdotes of early-stage, screen-detected cancer for which screening was not lifesaving on the demand for mammography.